2023-08-28 07:27:49 ET
More on ANI
- ANI Pharmaceuticals, Inc. ( ANIP ) Q2 2023 Earnings Call Transcript
- ANI Pharmaceuticals Is Undervalued When Considering Their Unadvertised Pipeline
- ANI Pharmaceuticals: Strong Revenue Growth And ANDA Approvals
- ANI Pharmaceuticals Non-GAAP EPS of $1.28 beats by $0.61, revenue of $116.5M beats by $16.64M
- ANI Pharma gains as FDA clears generics for Celontin and Fosamax
- ANI Pharmaceuticals soars ~10% after Q1 beat, raises outlook amid rare disease focus
For further details see:
ANI Pharma granted FDA nod for generic Estradiol Gel